Barclays PLC Has $643,000 Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Barclays PLC grew its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 64.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 156,267 shares of the company's stock after purchasing an additional 61,035 shares during the period. Barclays PLC owned about 0.20% of Trevi Therapeutics worth $643,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Trevi Therapeutics by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 1,299,322 shares of the company's stock valued at $5,354,000 after acquiring an additional 35,156 shares in the last quarter. Rosalind Advisors Inc. lifted its position in Trevi Therapeutics by 41.7% in the 4th quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company's stock valued at $4,378,000 after acquiring an additional 312,500 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Trevi Therapeutics by 120.5% in the 4th quarter. JPMorgan Chase & Co. now owns 221,664 shares of the company's stock valued at $913,000 after acquiring an additional 121,147 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Trevi Therapeutics by 14.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock valued at $713,000 after acquiring an additional 22,145 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock valued at $578,000 after acquiring an additional 2,935 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock traded down $0.23 during trading hours on Tuesday, hitting $6.47. The company had a trading volume of 197,376 shares, compared to its average volume of 1,164,895. The firm has a market cap of $646.31 million, a PE ratio of -14.70 and a beta of 0.62. Trevi Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.39. The firm has a 50-day moving average of $6.20 and a 200 day moving average of $4.56.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. As a group, research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on TRVI. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. B. Riley reissued a "buy" rating and set a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. D. Boral Capital reissued a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $17.56.

Insiders Place Their Bets

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This represents a 2.41% decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.37% of the company's stock.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.